A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT05219721 ↗

Phase 1 Recruiting 18 enrolled Chunrui Li Nanjing IASO Biotechnology Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, dose-exploration study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or plasma cell leukemia.

Timeline

Start: 2022-03-17
Primary completion: 2025-09-01
Completion: 2025-10-01

Publications

Pan M, Wang D, Xu J, Jin S, Wang Y, Tao Y, Liu Y, Ouyang W, Weng X, Yi H, Huang Y, Cao X, Li S, Zhang F, Zhang W, Li C, Mi JQ. The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma. Blood. 2026 Jan 29;147(5):513-519. doi: 10.1182/blood.2025030559.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR-GPRC5D	Cell therapy	1e+06 cells/kg	—
Subject	CAR-GPRC5D	Cell therapy	2e+06 cells/kg	—
Subject	CAR-GPRC5D	Cell therapy	3e+06 cells/kg	—

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Summary

Timeline

Publications

Drugs

Indications